Vicki Huff

Department of SVP, CSO Office, Division of SVP, CSO Office

About Dr. Vicki Huff

Dr. Huff is a Professor in the Department of Genetics and the Director of MD Anderson's Advanced Technology Genomics Core. Her research program revolves around understanding the genetic etiology of human diseases, in particular cancer, by direct analysis of human patients (and their tumors) and by generating and using mouse models that carry alterations known to occur in humans in order to identify the aberrant mechanisms and biological processes that result in disease. Historically the lab's focus has been on the genetics of a childhood kidney cancer, Wilms tumor (WT), identifying both germline and somatic alterations important in tumor etiology and understanding how these alterations impair normal kidney development, resulting in tumorigenesis. Other areas of research have included understanding the role of WT1 in renal failure and aberrant testicular development and the role of CTNNB1 in liver development and both pediatric and adult liver cancers.

View a complete list of Dr. Huff's publications.

Primary Appointment

Director, Advanced Technology Genomics Core, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX

Professor, Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Director, Advanced Technology Genomics Core, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX

Professor, Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Human disease genetics
Cancer genetics
Familial cancer predisposition
Kidney and liver development
Mouse models for kidney and liver cancer

My research program focuses on identifying and understanding the normal function of genes whose alteration is a critical step during tumorigenesis. The model system I am using is Wilms tumor (WT), a childhood cancer of the kidney. One Wilms tumor gene, WT1, has been isolated, and we have identified germline and somatic mutations at this locus in roughly 20% of Wilms tumor cases. WT1 encodes a zinc finger transcription factor that is essential for normal embryonal development. Children heterozygous for germline WT1 mutations often display genitourinary anomalies and, depending upon the mutation, early onset renal failure.

We are investigating WT1 function in tumorigenesis and development using a combination of approaches, including mutational analysis of primary human tumors, development of mouse strains carrying WT1 mutations observed in humans and gene expression arrays. From this work we know that WT1 mutations are strongly associated with alteration of the wnt signaling pathway and that WT1 mutation results in a distinctive gene expression profile and loss of heterozygosity profile in tumors. We have generated a mutant mouse strain carrying a common missense mutation observed in WT patients (R394W) and have determined that heterozygous mutant mice develop early onset renal failure with a pathology and disease course identical to that in patients. We are now using this model to identify the early changes in gene expression that initiate the process of glomerulosclerosis and renal failure. We have also generated a mouse strain carrying a conditional knock-out Wt1 allele and are using this strain to investigate the role of Wt1 in the development and subsequent normal function of the kidney, ovaries and testes. Recently we have determined that ablation of Wt1 function in the committed testes results in complete loss of testes architecture, germ cells and Sertoli cells. Current experiments are now focused on understanding the molecular and cellular consequences of Wt1 ablation in the testes.

My laboratory has also determined that WT1 is not responsible for the Wilms tumor predisposition observed in most families, demonstrating that predisposition to Wilms tumor is genetically heterogeneous. We have successfully localized to chromosome 19q the gene (FWT2) responsible for inherited predisposition to Wilms tumor in many families and are now sublocalizing it with the goals of isolating the gene, elucidating its role in normal and tumor development and understanding its role in tumorigenesis. Overall, these studies will help to elucidate the genes and cellular pathways critical for the regulation of cell growth and differentiation in normal kidney and how those functions are abrogated during tumorigenesis.

View a complete list of Dr. Huff's publications.

Education & Training

Degree-Granting Education

1987	University of Michigan, Ann Arbor, Michigan, US, Human Genetics, Ph.D
1983	University of Michigan, Ann Arbor, Michigan, US, Human Genetics, M.S
1976	University of Tennessee, Knoxville, Tennessee, US, Zoology, B.A

Postgraduate Training

1987-1990

Postdoctoral Fellowship, Biochemistry & Molecular Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Molecular Genetics/Cancer Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2001 - 2008

Associate Professor, Department of Experimental Pediatrics, UT M.D. Anderson Cancer Center, Houston, TX, 1999 - 2001

Assistant Professor, Department of Experimental Pediatrics, UT M.D. Anderson Cancer Center, Houston, TX, 1993 - 1999

Research Associate, Department of Biochemistry and Molecular Biology, UT M.D. Anderson Cancer Center, Houston, TX, 1990 - 1993

Other Professional Positions

Member, Houston Forensic Science Center Board, Houston, TX, 2018 - Present

Member, Curriculum and Training Working Group, UT Graduate School of Biomedical Sciences, Houston, TX, 2016 - 2017

Member, The Hackett Center for Mental Health Leadership Cabinet, Houston, TX, 2016 - 2021

Interviewer, UTHSCH MD/PhD Program, Houston, TX, 2014 - 2021

Reviewer, Multidisciplinary Research Program proposal, Houston, TX, 2014

Member, Health Sciences Center Faculty Intercouncil, Houston, TX, 2012 - 2014

Chair, Renal Tumor Biology Committee, Children's Oncology Group (COG), 2010 - 2021

Judge, Genes and Development Annual Retreat Poster Competition, Houston, TX, 2010

Judge, Genes and Development/Carcinogenesis Joint Retreat Poster Competition, Houston, TX, 2009

Co-coordinator, Scientific Retreat for GSBS Program in Genes & Development, UT Graduate School of Biomedical Sciences, Houston, TX, 2007 - 2008

Co-coordinator, Scientific Retreat for GSBS Program in Genes & Development, UT Graduate School of Biomedical Sciences, Houston, TX, 2006 - 2007

Judge, Human Molecular Genetics Program Symposium Poster Competition, Houston, TX, 2003 - 2005

Member, Renal Tumor Biology Committee, Children's Oncology Group (COG), 2002 - Present

Member, External Advisory Committee, Southern California Environmental Health Sciences Center, Los Angeles, CA, 1998 - Present

Member, Research Planning Meeting, Radiation Effects Research Foundation, Hiroshima, 1997

External Advisory Committee, NIEHS Center, University of Southern California, Los Angeles, CA, 1996 - 2013

Member, Childhood Cancer Group Soft Tissue Tumor Strategy Group, 1996 - 2002

Member, Genetic Cancer Predisposition Section Program Committee, 1997 AACR Annual Meeting, 1996

Member, National Wilms Tumor Study Group (subsumed in COG), 1993 - 2002

Member, Childhood Cancer Group Wilms Tumor Strategy Group, 1993 - 1996

Project Advisory Committee for NIH grant, Insurance Implication of the Human Genome Mapping Project, 1991 - 1994

Extramural Institutional Committee Activities

Member, Single Cell Sequencing Core Advisory Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, Faculty Appeals Panel/Research Integrity, The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, Steering Committee, Genetics & Epigenetics Program, UT Graduate School of Biomedical Sciences, 2017 - 2018

Member, Executive Committee, UT Graduate School of Biomedical Sciences, 2016 - 2018

Member, Technology Task Force Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2020

Chair, Academic Standards Committee, UT Graduate School of Biomedical Sciences, 2015 - 2016

Member, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2016

Reviewer, INTEREST Grant Review, The University of Texas MD Anderson Cancer Center, 2015

Member, Department of Epidemiology Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Chair, NGS LIMS Request for Projects Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2017

Co-Facilitator, Women Faculty Program Career Development Workshop, The University of Texas MD Anderson Cancer Center, 2013

Member, Award Review Committee, Genes and Development Program, UT Graduate School of Biomedical Sciences, 2013 - 2015

Chair, Curriculum Committee, Human and Molecular Genetics Program, UT Graduate School of Biomedical Sciences, 2013 - 2015

Member, Academic Standards Committee, UT Graduate School of Biomedical Sciences, 2013 - 2015

Panelist, Tenure Track Research Promotion & Tenure Panel Discussion, Faculty Mentoring Day, The University of Texas MD Anderson Cancer Center, 2012

Member, RPPA Core Facility Oversight Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present

Member, Steering Committee, Human and Molecular Genetics Program, UT Graduate School of Biomedical Sciences, 2012 - 2014

Research Mentor, Faculty Development Office, Speed Mentoring Session, The University of Texas MD Anderson Cancer Center, 2012

Director, Advanced Genomic Technologies (formerly Sequencing and Microarray Facility), The University of Texas MD Anderson Cancer Center, 2011 - Present

Director, DNA Analysis Core-Consolidated with Array Core, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Research Mentor, Faculty Development Office, Speed Mentoring Session, The University of Texas MD Anderson Cancer Center, 2011

Reviewer, Bridge Fund, The University of Texas MD Anderson Cancer Center, 2010

Member, Tenure Track Progress Review Committee for Dr. Patrick Lennon, The University of Texas MD Anderson Cancer Center, 2010

Member, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2012

Member, Faculty Achievement Award Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2011

Chair, Department of Genetics Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2010

Reviewer, Odyssey Postdoctoral Applications, The University of Texas MD Anderson Cancer Center, 2009 - 2010

Member, Review Panel for Astra-Zeneca MDACC Strategic Alliance LOIs, The University of Texas MD Anderson Cancer Center, 2009

Member, Study Section Review Committee for Basic Research Projects, The University of Texas MD Anderson Cancer Center, 2008 - 2012

Member, Oversight Committee, NIH Training Grant in Genetics, The University of Texas MD Anderson Cancer Center, 2008 - 2015

Member, Odyssey Program Advisory Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2011

Member, Non-Tenure Track Progress Review Committee for Dr. Mini Kapoor, The University of Texas MD Anderson Cancer Center, 2008

Member, Non-Tenure Track Progress Review Committee for Dr. Sonali Sonnyal, The University of Texas MD Anderson Cancer Center, 2008

Member, Department of Cancer Genetics Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2007

Member, Non-Tenure Track Progress Review Committee for Dr. Katherine Naff, The University of Texas MD Anderson Cancer Center, 2007

Member, Genomics Core Users Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2012

Member, Review Committee for Pre-Doctoral Abstracts & Posters for MDACC Trainee Day, The University of Texas MD Anderson Cancer Center, 2005

Member, Membership Committee, UT Graduate School of Biomedical Sciences, 2004 - 2006

Member, Mid-Tenure Review Committee for Dr. Warwick Daw, The University of Texas MD Anderson Cancer Center, 2004

Member, MDACC DNA Analysis Core Facility Oversight Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2005

Member, MDACC Mouse Array Core Facility Oversight Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2005

Member, Steering Committee, Human and Molecular Genetics, UT Graduate School of Biomedical Sciences, 2001 - 2004

Member, MDACC Institutional Biosafety Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2004

Chair, Written Candidacy Examination Committee, Human and Molecular Genetics, UT Graduate School of Biomedical Sciences, 2001

Member, Department of Molecular Genetics/Cancer Genetics Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2001

Member, Division of Pediatrics Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2000

Member, Study Section Review Committee for Basic Research Projects, The University of Texas MD Anderson Cancer Center, 1999 - 2002

Member, Division of Pediatrics Executive Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2001

Member, Curriculum Committee, Human Molecular Genetics Program, UT Graduate School of Biomedical Sciences, 1998 - 2001

Chair, Curriculum Committee, Human Molecular Genetics Program, UT Graduate School of Biomedical Sciences, 1998 - 2001

Member, Review Committee for Faculty Research Achievement Awards, The University of Texas MD Anderson Cancer Center, 1996

Member, Office of Education Faculty Committee to Review Clinical Trainee Research Fund Applications, The University of Texas MD Anderson Cancer Center, 1996

Member, Office of Education Faculty Committee to Review Clinical Trainee Research Fund Applications, The University of Texas MD Anderson Cancer Center, 1995

Ad Hoc Representative, Faculty Senate, The University of Texas MD Anderson Cancer Center, 1994 - 1999

Ad Hoc Member, Tenure and Promotions Committee, The University of Texas MD Anderson Cancer Center, 1994

Honors & Awards

1998	Dean's Excellence Award
1990 - 1992	University Cancer Foundation Fellow
1987 - 1990	NIH Postdoctoral fellowship
1985 - 1986	Rackham Predoctoral Fellowship

Professional Memberships

Member, American Society of Microbiology

2004 - Present

Member, American Association for Cancer Research

1993 - Present

Member, American Society of Human Genetics

1987 - Present

Member, American Association for the Advancement of Science

1976 - Present

Selected Presentations & Talks

Local Presentations

2018. DNA Sequencing Core. Conference. Cancer Center Support Grant (CCSG) Cancer Genetics & Epigenetics Program Retreat. Houston, TX, US.
2009. Use of LOH for Patient Stratification in Wilms Tumor. Conference. Houston, TX, US.
2009. Clinical Trials Faculty Meeting. Conference. Houston, TX, US.
2008. Genetics of Frazier's Syndrome. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2008. Genetics of Wilms Tumor. Conference. Houston, TX, US.
2001. Wilms' Tumor. Conference. Houston, TX, US.
1999. Wilms' Tumor. Invited. Houston, TX, US.
1999. Cancer Survivor Group. Conference. Houston, TX, US.
1997. Wilms' Tumor. Invited. Houston, TX, US.
1996. Genetics of Cancer. Conference. Houston, TX, US.
1995. Laboratory Tour for Students. Institute for Diversity in Health Management. Houston, TX, US.
1994. Genetics in Society. Conference. Houston, TX, US.
1993. Students with Interest in Medical Sciences. Conference. Cypress Springs High School. Houston, TX, US.
1991. Wilms' Tumor. Houston, TX, US.

Regional Presentations

2012. Impact of Kidney Progenitor Cell Differentiation Status in Wilms Tumorigenesis. Conference. CPRIT Annual Symposium. Austin, TX, US.
2012. Genetic Alterations in a Childhood Cancer. Invited. CPRIT Annual Meeting. Austin, TX, US.
2011. Impact of Kidney Progenitor Cell Differentiation Status in Wilms Tumorigenesis. Conference. CPRIT Annual Symposium. Austin, TX, US.
1998. Wilms' Tumor. Invited. Ann Arbor, MI, US.
1997. Wilms' Tumor. Invited. Portland, OR, US.
1996. Wilms' Tumor. Invited. Tibodaux, LA, US.
1996. Genetics of Cancer. Conference. Austin, TX, US.
1994. Wilms' Tumor. Invited. Chicago, IL, US.
1992. Wilms' Tumor. Invited. Seattle, WA, US.
1990. Wilms' Tumor. Invited. Ann Arbor, MI, US.

National Presentations

2018. WAGR - Next Steps. Invited. Ann Arbor, MI, US.
2017. WAGR – Genetics and WT1 Mutations. Invited. Ann Arbor, MI, US.
2009. Wilms Tumor. Invited. Children's Oncology Group. Dallas, TX, US.
2009. Wilms' Tumor. Invited. Anaplastic Wilms Tumor and Rhabdoid Tumor meeting. Bethesda, MD, US.
2006. Wilms' Tumor. Invited. Plenary Session,. San Diego, CA, US.
2005. Wilms' Tumor. Invited. Renal Tumors Committee. Los Angeles, CA, US.
1997. Wilms' Tumor. Invited. Minneapolis, MN, US.
1997. Wilms' Tumor. Invited. Houston, TX, US.
1996. Wilms' Tumor. Invited. Seattle, WA, US.
1994. Wilms' Tumor. Invited. Rockville, MD, US.
1994. Annual meeting. Conference. American Society of Human Genetics, US.
1994. Wilms' Tumor. Invited. Seattle, WA, US.
1993. Wilms' Tumor. Invited. San Francisco, CA, US.
1993. Wilms' Tumor. Invited. Seattle, WA, US.
1992. Wilms' Tumor. Invited. Bethesda, MD, US.
1992. Wilms' Tumor. Invited. Pittsburgh, PA, US.
1992. Wilms' Tumor. Invited. La Jolla, CA, US.
1992. Wilms' Tumor. Invited. Bethesda, MD, US.
1990. Annual meeting. Conference. American Society of Human Genetics, US.
1989. Annual meeting. Conference. American Society of Human Genetics, US.
1989. Wilms' Tumor. Invited. Washington, DC, US.
1988. Annual meeting. Conference. American Society of Human Genetics. New Orleans, LA, US.
1987. Annual meeting. Conference. American Society of Human Genetics. San Diego, CA, US.

International Presentations

2022. A Framework for Understanding Wilms Tumor Molecular Genetics to Improve Clinical Care,. Invited. 11th International Renal Tumor Biology Meeting. Marseilles, FR.
2020. Genetically Engineered Mouse (GEM) Models for Wilms Tumor (Virtual). Invited. 10th International Renal Tumor Biology Meeting, US.
2020. Using the Wt1-Igf2 Wilms tumor mouse model to understand tumor development and explore patient care options (Virtual). Invited. IWAGR international meeting, US.
2016. Nephron progenitor but not stromal progenitor cells give rise to Wilms tumors in mouse models with beta-catenin activation or Wt1 ablation and Igf2 upregulation. Invited. 9th International Renal Tumor Biology Meeting. Toronto, CA.
2011. Wilms Tumors: about Tumor Suppressor Genes, an Oncogene and a Chameleon Gene. Invited. Fifth International Conference on WT1 in Human Neoplasia. Torino, IT.
2010. Presidential Symposium of 26th Annual Meeting. Invited. Japanese Society of Pediatric Oncology. Osaka, JP.
2008. Renal Tumors. Invited. 6th International Renal Tumor Biology Meeting. Chamonix, FR.
2002. Wilms' Tumor. Invited. London, GB.
2000. Wilms' Tumor. Invited. Rome, IT.
1999. Wilms' Tumor. Invited. Philadelphia, US.
1998. Wilms' Tumor. Invited. Hong Kong, CN.
1995. Wilms' Tumor. Invited. Philadelphia, US.
1991. Annual meeting. Conference. International Society of Human Genetics. Washington, US.
1991. Wilms' Tumor. Invited. Paris, FR.
1990. Wilms' Tumor. Invited. Edinburgh.

Formal Peers

2024. Translational Research Methods for Surgical Oncology Residents and Fellows (Virtual). Houston, Texas, US.
2015. WT1 in Kidney Development and Human Disease. Invited. Houston, TX, US.
2014. WT1 in Kidney Development and Human Disease. Invited. Dallas, TX, US.
2014. Modeling a Cancer Associated with Aberrant Development. Invited. New York City, NY, US.
2011. Creating Mouse Models of WT1-Associated Human Disease. Invited. New York City, NY, US.
2011. Creating Mouse Models for a Childhood Cancer. Invited. Houston, TX, US.
2009. Wilms' Tumor. Invited. Houston, TX, US.
2008. Wilms' Tumor. Invited. Houston, TX, US.
2005. Wilms' Tumor. Invited. San Antonio, TX, US.
2004. Wilms' Tumor. Invited. Houston, TX, US.
2001. Wilms' Tumor. Invited. Houston, TX, US.
1999. Wilms' Tumor. Invited. Houston, TX, US.

Less

Grant & Contract Support

Date:	2020 - 2021
Title:	Metformin as a cancer preventive agent for Wilms tumor
Funding Source:	Pablove Foundation
Role:	PI
ID:	F00010253

Date:	2019 - 2021
Title:	Identification of genetic changes associated with relapse and/or adaptive resistance in patients registered as Favorable Histology Wilms tumor on AREN03B2
Funding Source:	Leidos Biomedical Research, Inc
Role:	Collaborator
ID:	FP00008208

Date:	2018 - 2023
Title:	Integrated Single Cell Genomics Core Facility
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP180684

Date:	2018 - 2019
Title:	NovaSeq6000
Funding Source:	NIH
Role:	PI

Date:	2013 - 2017
Title:	Children's Oncology Group - Renal Tumor Biology Study
Funding Source:	NIH/NCI
Role:	Chair
ID:	CA98543 09

Date:	2012 - 2017
Title:	Late effects of treatment in Wilms tumor survivors and offspring
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	CA054498

Date:	2011 - 2013
Title:	NO TITLE PROVIDED
Funding Source:	SINF
Role:	PI

Date:	2011 - 2014
Title:	Impact of differentiation status on tumorigenesis
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP110324

Date:	2010 - 2013
Title:	Next Generation genomic Sequence Identification of the 19q Familial Wilms Tumor Predisposition Gene
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP100329

Date:	2009 - 2012
Title:	TARGET: Wilms Tumor
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	CA09843-07S6

Date:	2008 - 2011
Title:	Predoctoral Fellow in Dr Huff's lab
Funding Source:	NIH/NCI
Role:	Mentor

Date:	2006 - 2011
Title:	A Mouse Model for Glomerulosclerosis and Early Onset Renal Failure
Funding Source:	NIH/NIDDK
Role:	PI
ID:	DK069599

Date:	2006 - 2012
Title:	Nucleic Acids Isolation and DNA Analysis Facility
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	CA34936

Date:	2006 - 2011
Title:	Molecular Genetic Pathways in Wilms Tumor Development
Funding Source:	NIH/NCI
Role:	PI
ID:	CA34936

Date:	2006 - 2007
Title:	Investigation of the Paradoxical Role of WT1 in Tumorigenesis and Kidney Development Using a Novel Mouse Model
Funding Source:	MDACC Institutional Research Grant
Role:	Principal Investigator-MDACC

Date:	2004 - 2006
Title:	Molecular Genetic Pathways in Wilms Tumor Development
Funding Source:	NCI (interim Funding)
Role:	PI
ID:	CA34936

Date:	2004 - 2006
Title:	Nucleic Acids Isolation and DNA analysis Facility Core D
Funding Source:	NCI (Interim Funding)
Role:	Core Leader

Date:	1999 - 2004
Title:	Role of WT1 in Genitourinary Development and Tumorigenesis
Funding Source:	NCI
Role:	PI
ID:	34936

Date:	1999 - 2004
Title:	Wilms Tumor
Funding Source:	NCI
Role:	PI
ID:	34936

Date:	1999 - 2006
Title:	Molecular Investigation of Familial Wilms Tumor
Funding Source:	NCI
Role:	PI
ID:	CA78257-01

Date:	1998 - 2000
Title:	Familial Wilms Tumor: Recruitment of Families and Sublocalization of the 19q Predisposition Gene
Funding Source:	UTMDACC Human Cancer Genetics Research Award
Role:	PI

Date:	1998 - 2024
Title:	Cancer Center Support Grant Sequencing and MicroArray Facility
Funding Source:	NIH/NCI
Role:	Director
ID:	CA016672 36

Date:	1996 - 1997
Title:	Aberrant Splicing of WT1 Gene
Funding Source:	NCI
Role:	PI
ID:	CA42326

Date:	1993 - 1996
Title:	Biological Prognostic Variables in Wilms Tumor Patients
Funding Source:	NIH
Role:	PI
ID:	CA60114

Date:	1993 - 1998
Title:	Molecular Genetics of Wilms Tumor
Funding Source:	NCI
Role:	PI
ID:	CA34936

Date:	1992 - 1994
Title:	Detection and Characterization of WT1 Mutations in Wilms Tumor Patients
Funding Source:	PRS Clinical Research Grant
Role:	PI

Date:	1991 - 1993
Title:	Genetic Alterations in Neurofibromatosis Patients with Cancer
Funding Source:	Texas Neurofibromatosis Foundation
Role:	PI

Title:	NO TITLE PROVIDED
Funding Source:	MDACC Odyssey Program
Role:	Mentor

Title:	NO TITLE PROVIDED
Funding Source:	NIH
Role:	Mentor

Selected Publications

Peer-Reviewed Articles

Geller, JI, Renfro, LA, Grundy, PE, Perlman, EJ, Kalapurakal, JA, Ehrlich, PF, Biegel, J, Huff, VD, Warwick, A, Paulino, AC, Mullen, EA, Daw Bitar, N, Hoffer, FA, Tochner, Z, Gow, KW, Gratias, EJ, Ward, D, Anderson, JR, Fernandez, CV, Dome, JS. Rhabdoid Tumor of the Kidney and Soft Tissues. Pediatric Blood and Cancer 72(3), 2025. e-Pub 2025. PMID: 39702900.
Aloway JA, Ruteshouser EC, Huff V, Behringer RR. Generation of a Wt1 conditional deletion, nuclear red fluorescent protein reporter allele in the mouse. Differentiation 138:100791, 2024. e-Pub 2024. PMID: 38941819.
Garner M, Rajani B, Vaidya P, Dayeh SA, Cecchi AC, Miyake CC, Huff V, Wanat M, Wang E, Kurzlechner LM, Landstrom AP, An D, Liang Y, Moulik M, Wong TC, Cunha SR, Cannon A, Holt RL, Milewicz DM, Prakash SK. The UTHealth Houston Adult Cardiovascular Genomics Certificate Program: Efficacy and Impact on Healthcare Professionals. Res Sq, 2024. e-Pub 2024. PMID: 38947076.
Murphy AJ, Cheng C, Williams J, Shaw TI, Pinto EM, Dieseldorff-Jones K, Brzezinski J, Renfro LA, Tornwall B, Huff V, Hong AL, Mullen EA, Crompton B, Dome JS, Fernandez CV, Geller JI, Ehrlich PF, Mulder H, Oak N, Maciezsek J, Jablonowski CM, Fleming AM, Pichavaram P, Morton CL, Easton J, Nichols KE, Clay MR, Santiago T, Zhang J, Yang J, Zambetti GP, Wang Z, Davidoff AM, Chen X. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q. Nat Commun 14(1):8006, 2023. e-Pub 2023. PMID: 38110397.
Murphy AJ, Cheng C, Williams J, Shaw TI, Pinto EM, Dieseldorff-Jones K, Brzezinski J, Renfro LA, Tornwall B, Huff V, Hong AL, Mullen EA, Crompton B, Dome JS, Fernandez CV, Geller JI, Ehrlich PF, Mulder H, Oak N, Maciezsek J, Jablonowski C, Fleming AM, Pichavaram P, Morton CL, Easton J, Nichols KE, Clay MR, Santiago T, Zhang J, Yang J, Zambetti GP, Wang Z, Davidoff AM, Chen X. The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children's Oncology Group AREN18B5-Q Study. Res Sq, 2023. e-Pub 2023. PMID: 36993649.
Gadd S, Huff V, Skol AD, Renfro LA, Fernandez CV, Mullen EA, Jones CD, Hoadley KA, Yap KL, Ramirez NC, Aris S, Phung QH, Perlman EJ. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study. Cell Rep Med 3(6):100644, 2022. e-Pub 2022. PMID: 35617957.
Mariottini C, Munari L, Gunzel E, Seco JM, Tzavaras N, Hansen J, Stern SA, Gao V, Aleyasin H, Sharma A, Azeloglu EU, Hodes GE, Russo SJ, Huff V, Birtwistle MR, Blitzer RD, Alberini CM, Iyengar R. Wilm's tumor 1 promotes memory flexibility. Nat Commun 10(1):3756, 2019. e-Pub 2019. PMID: 31434897.
Annesley CE, Rabik C, Duffield AS, Rau RE, Magoon D, Li L, Huff V, Small D, Loeb DM, Brown P. Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget 9(82):35313-35326, 2018. e-Pub 2018. PMID: 30450160.
Armstrong AE, Gadd S, Huff V, Gerhard DS, Dome JS, Perlman EJ. A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study. PLoS One 13(12):e0208936, 2018. e-Pub 2018. PMID: 30543698.
Gadd S, Huff V, Walz AL, AHAG O, Armstrong AE, Gerhard DS, Smith MA, Auvil JMG, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Hermida LC, Davidsen T, Gesuwan P, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Dome JS, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Ross N, Gastier-Foster JM, Arold ST, Perlman EJ. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet 49(10):1487-1494, 2017. e-Pub 2017. PMID: 28825729.
Fernandez CV, Perlman EJ, Mullen EA, Chi YY, Hamilton TE, Gow KW, Ferrer FA, Barnhart DC, Ehrlich PF, Khanna G, Kalapurakal JA, Bocking T, Huff V, Tian J, Geller JI, Grundy PE, Anderson JR, Dome JS, Shamberger RC. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. Ann Surg 265(4):835-840, 2017. e-Pub 2017. PMID: 27811504.
Chen M, Zhang L, Cui X, Lin X, Li Y, Wang Y, Wang Y, Qin Y, Chen D, Han C, Zhou B, Huff V, Gao F. Wt1 directs the lineage specification of sertoli and granulosa cells by repressing Sf1 expression. Development 144(1):44-53, 2017. e-Pub 2017. PMID: 27888191.
Ooms AH, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Huff V, Dome JS, Chi YY, Tian J, Geller JI, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Walz AL, van den Heuvel-Eibrink MM, de Krijger RR, Ross N, Gastier-Foster JM, Perlman EJ. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clin Cancer Res 22(22):5582-5591, 2016. e-Pub 2016. PMID: 27702824.
Palculict TB, Ruteshouser EC, Fan Y, Wang W, Strong L, Huff V. Identification of germline DICER1 mutations and loss of heterozygosity in familial Wilms tumour. J Med Genet 53(6):385-8, 2016. e-Pub 2016. PMID: 26566882.
Huang L, Mokkapati S, Hu Q, Ruteshouser EC, Hicks MJ, Huff V. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation. Neoplasia 18(2):71-81, 2016. e-Pub 2016. PMID: 26936393.
Perlman EJ, Gadd S, Arold ST, Radhakrishnan A, Gerhard DS, Jennings L, Huff V, Guidry Auvil JM, Davidsen TM, Dome JS, Meerzaman D, Hsu CH, Nguyen C, Anderson J, Ma Y, Mungall AJ, Moore RA, Marra MA, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Gastier-Foster JM, Ross N, Smith MA. MLLT1 YEATS domain mutations in clinically distinctive favourable histology Wilms tumours. Nat Commun 6(10013):10013, 2015. e-Pub 2015. PMID: 26635203.
Zhang L, Chen M, Wen Q, Li Y, Wang Y, Wang Y, Qin Y, Cui X, Yang L, Huff V, Gao F. Reprogramming of sertoli cells to fetal-like leydig cells by Wt1 ablation. Proc Natl Acad Sci U S A 112(13):4003-8, 2015. e-Pub 2015. PMID: 25775596.
Walz AL, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Guidry Auvil JM, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Bowlby R, Brooks D, Ma Y, Mungall AJ, Moore RA, Schein J, Marra MA, Huff V, Dome JS, Chi YY, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Jafari N, Ross N, Gastier-Foster JM, Perlman EJ. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology wilms tumors. Cancer Cell 27(2):286-97, 2015. e-Pub 2015. PMID: 25670082.
Mokkapati S, Niopek K, Huang L, Cunniff KJ, Ruteshouser EC, deCaestecker M, Finegold MJ, Huff V. β-Catenin Activation in a Novel Liver Progenitor Cell Type Is Sufficient to Cause Hepatocellular Carcinoma and Hepatoblastoma. Cancer Res 74(16):4515-25, 2014. e-Pub 2014. PMID: 24848510.
Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Transl Oncol 7(4):484-92, 2014. e-Pub 2014. PMID: 24969538.
Shukrun R, Pode-Shakked N, Pleniceanu O, Omer D, Vax E, Peer E, Pri-Chen S, Jacob J, Hu Q, Harari-Steinberg O, Huff V, Dekel B. Wilms' tumor blastemal stem cells dedifferentiate to propagate the tumor bulk. Stem Cell Reports 3(1):24-33, 2014. e-Pub 2014. PMID: 25068119.
Libes JM, Seeley EH, Li M, Axt JR, Pierce J, Correa H, Newton M, Hansen E, Judd A, McDonald H, Caprioli RM, Naranjo A, Huff V, O'Neill JA, Lovvorn HN, Tumor Consortium KW. Race disparities in peptide profiles of North American and Kenyan Wilms tumor specimens. J Am Coll Surg 218(4):707-20, 2014. e-Pub 2014. PMID: 24655859.
Gao F, Zhang J, Wang X, Yang J, Chen D, Huff V, Liu YX. Wt1 functions in ovarian follicle development by regulating granulosa cell differentiation. Hum Mol Genet 23(2):333-41, 2014. e-Pub 2014. PMID: 24009315.
Wang XN, Li ZS, Ren Y, Jiang T, Wang YQ, Chen M, Zhang J, Hao JX, Wang YB, Sha RN, Huang Y, Liu X, Hu JC, Sun GQ, Li HG, Xiong CL, Xie J, Jiang ZM, Cai ZM, Wang J, Wang J, Huff V, Gui YT, Gao F. The Wilms tumor gene, Wt1, is critical for mouse spermatogenesis via regulation of sertoli cell polarity and is associated with non-obstructive azoospermia in humans. PLoS Genet 9(8):e1003645, 2013. e-Pub 2013. PMID: 23935527.
Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, Gratias EJ, Dix DB, Ehrlich PF, Khanna G, Malogolowkin MH, Anderson JR, Naranjo A, Perlman EJ, Committee COG. Children's Oncology Group's 2013 blueprint for research: renal tumors. Pediatr Blood Cancer 60(6):994-1000, 2013. e-Pub 2013. PMID: 23255438.
Kaftanovskaya EM, Neukirchner G, Huff V, Agoulnik AI. Left-sided cryptorchidism in mice with Wilms' tumour 1 gene deletion in gubernaculum testis. J Pathol 230(1):39-47, 2013. e-Pub 2013. PMID: 23288785.
Flores LG, Yeh HH, Soghomonyan S, Young D, Bankson J, Hu Q, Alauddin M, Huff V, Gelovani JG. Monitoring Therapy with MEK Inhibitor U0126 in a Novel Wilms Tumor Model in Wt1 Knockout Igf2 Transgenic Mice Using (18)F-FDG PET with Dual-Contrast Enhanced CT and MRI: Early Metabolic Response Without Inhibition of Tumor Growth. Mol Imaging Biol 15(2):175-85, 2013. e-Pub 2013. PMID: 22875335.
Peng G, Fan Y, Palculict TB, Shen P, Ruteshouser EC, Chi AK, Davis RW, Huff V, Scharfe C, Wang W. Rare variant detection using family-based sequencing analysis. Proc Natl Acad Sci U S A 110(10):3985-90, 2013. e-Pub 2013. PMID: 23426633.
Makki S, Ruteshouser EC, Huff V. Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target. Exp Cell Res 319(5):612-22, 2013. e-Pub 2013. PMID: 23291318.
Gadd S, Beezhold P, Jennings L, George D, Leuer K, Huang CC, Huff V, Tognon C, Sorensen PH, Triche T, Coffin CM, Perlman EJ. Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study. J Pathol 228(1):119-30, 2012. e-Pub 2012. PMID: 22374738.
Gadd S, Huff V, Huang CC, Ruteshouser EC, Dome JS, Grundy PE, Breslow N, Jennings L, Green DM, Beckwith JB, Perlman EJ. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study. Neoplasia 14(8):742-56, 2012. e-Pub 2012. PMID: 22952427.
Perlman EJ, Grundy PE, Anderson JR, Jennings LJ, Green DM, Dome JS, Shamberger RC, Ruteshouser EC, Huff V. WT1 mutation and 11p loss of heterozygosity predict relapse in very low risk Wilms tumors treated by surgery alone. J Clin Oncol 29(6):698-703, 2011. e-Pub 2011. PMID: 21189373.
Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar A, Stewart J, Strong LC, Behringer RR, Huff V. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest 121(1):174-83, 2011. e-Pub 2011. PMID: 21123950.
Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, Subramanian A, Hinkle G, Yang X, Saif S, Root DE, Huff V, Hahn WC, Sweet-Cordero EA. Wilms tumor -1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human. J Clin Invest 120(11):3940-52, 2010. e-Pub 2010. PMID: 20972333.
Shamberger RC, Anderson JR, Breslow NE, Perlman EJ, Beckwith JB, Ritchey ML, Haase GM, Donaldson M, Grundy PE, Weetman R, Coppes MJ, Malogolowkin M, Shearer PD, Kletzel M, Thomas PR, Macklis R, Huff V, Weeks DA, Green DM. Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. Ann Surg 251(3):555-8, 2010. e-Pub 2010. PMID: 20142733.
Subbiah V, Huff V, Wolff JE, Ketonen L, Lang FF, Stewart J, Langford L, Herzog CE. Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1 GT-IVS9 mutation: A 46 XY phenotypic female with Frasier syndrome. Pediatr Blood Cancer 53(7):1349-1351, 2009. e-Pub 2009. PMID: 19653292.
Drake KM, Ruteshouser EC, Natrajan R, Harbor P, Wegert J, Gessler M, Pritchard-Jones K, Grundy P, Dome J, Huff V, Jones C, Aldred MA. Loss of heterozygosity at 2q37 in sporadic Wilms tumor: a putative role for miR-562. Clin Cancer Res 15(19):5985-92, 2009. e-Pub 2009. PMID: 19789318.
Katzman PJ, Arnold GL, Lagoe EC, Huff V. Universal nephroblastomatosis with bilateral hyperplastic nephromegaly in siblings. Pediatr Dev Pathol 12(1):1, 2009. e-Pub 2009. PMID: 18275253.
Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47(6):461-70, 2008. e-Pub 2008. PMID: 18311776.
Chang H, Gao F, Guillou F, Taketo MM, Huff V, Behringer RR. Wt1 negatively regulates beta-catenin signaling during testis development. Development 135(10):1875-85, 2008. e-Pub 2008. PMID: 18403409.
Malogolwkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Anigio GJ, Beckwith JB, Shamberger RC, Haase GM, Donaldson M, Weetman R, Coppes MJ, Shearer P, Coccia P, Kletzel M, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 50(2):236-241, 2008. e-Pub 2008. PMID: 17539021.
Green DM, Cotton CA, Malogolowkin M, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PR, Grundy PE, D'Angio GJ, Beckwith JAB, Shamberger RC, Haase GM, Donaldson M, Weetman R, Coppes MJ, Shearer P, Coccia P, Kletzel M, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 48(5):493-9, 2007. e-Pub 2007. PMID: 16547940.
Huff V. Wilms tumor genetics: A new, UnX-pected twist to the story. Cancer Cell 11(2):105-7, 2007. e-Pub 2007. PMID: 17292822.
Gao F, Maiti S, Alam N, Zhang Z, Deng JM, Behringer RR, Lecureuil C, Guillou F, Huff V. The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the developing testis. Proc Natl Acad Sci U S A 103(32):11987-92, 2006. e-Pub 2006. PMID: 16877546.
Ruteshouser EC, Hendrickson BW, Colella S, Krahe R, Pinto L, Huff V. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors. Genes Chromosomes Cancer 43(2):172-80, 2005. e-Pub 2005. PMID: 15761866.
Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 23(29):7312-21, 2005. e-Pub 2005. PMID: 16129848.
Gao F, Maiti S, Sun G, Ordonez NG, Udtha M, Deng JM, Behringer RR, Huff V. The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome. Mol Cell Biol 24(22):9899-910, 2004. e-Pub 2004. PMID: 15509792.
Royer-Pokora B, Beier M, Henzler M, Alam R, Schumacher V, Weirich A, Huff V. Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. Am J Med Genet A 127(3):249-57, 2004. e-Pub 2004. PMID: 15150775.
Anderson CE, Punnett HH, Huff V, de Chadarevian JP. Characterization of a Wilms tumor in a 9-year-old girl with trisomy 18. Am J Med Genet A 121(1):52-5, 2003. e-Pub 2003. PMID: 12900902.
Udtha M, Lee SJ, Alam R, Coombes K, Huff V. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors. Oncogene 22(24):3821-6, 2003. e-Pub 2003. PMID: 12802290.
Green DM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Perlman E, Donaldson M, Grundy PE, Weetman R, Coppes MJ, Malogolowkin M, Shearer P, Coccia P, Kletzel M, Thomas PR, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 19(17):3719-24, 2001. e-Pub 2001. PMID: 11533093.
Ruteshouser EC, Ashworth LK, Huff V. Absence of PPP2R1A mutations in Wilms tumor. Oncogene 20(16):2050-4, 2001. e-Pub 2001. PMID: 11360189.
Dharnidharka VR, Ruteshouser EC, Rosen S, Kozakewich H, Harris HW, Jr, Herrin JT, Huff V. Pulmonary dysplasia, Denys-Drash syndrome and Wilms tumor 1 gene mutation in twins. Pediatr Nephrol 16(3):227-31, 2001. e-Pub 2001. PMID: 11322369.
Hussong JW, Perkins SL, Huff V, McDonald JM, Pysher TJ, Beckwith JB, Coffin CM. Familial Wilms' tumor with neural elements: characterization by histology, immunohistochemistry, and genetic analysis. Pediatr Dev Pathol 3(6):561-7, 2000. e-Pub 2000. PMID: 11000334.
Maiti S, Alam R, Amos CI, Huff V. Frequent association of B-catenin and WT1 mutations in Wilms tumors. Cancer Res 60(22):6288-92, 2000. e-Pub 2000. PMID: 11103785.
Chao LY, Huff V, Strong LC, Saunders GF. Mutation in the PAX6 gene in twenty patients with aniridia. Hum Mutat 15(4):332-9, 2000. e-Pub 2000. PMID: 10737978.
El-Naggar AK, Lai S, Tucker SA, Clayman GL, Goepfert H, Hong WK, Huff V. Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinoma. Oncogene 18(50):7063-9, 1999. e-Pub 1999. PMID: 10597307.
McDonald JM, Douglass EC, Fisher R, Geiser CF, Krill CE, Strong LC, Virshup D, Huff V. Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res 58(7):1387-90, 1998. e-Pub 1998. PMID: 9537236.
Huff V, Amos CI, Douglass EC, Fisher R, Geiser CF, Krill CE, Li FP, Strong LC, McDonald JM. Evidence for genetic heterogeneity in familial Wilms' tumor. Cancer Res 57(10):1859-62, 1997. e-Pub 1997. PMID: 9157975.
Huff V. Genotype/phenotype correlations in Wilms' tumor. Med Pediatr Oncol 27(5):408-14, 1996. e-Pub 1996. PMID: 8827067.
Gunning KB, Cohn SL, Tomlinson GE, Strong LC, Huff V. Analysis of possible abnormal WT1 RNA processing in primary Wilms tumors. Oncogene 13(6):1179-85, 1996. e-Pub 1996. PMID: 8808692.
El-Naggar AK, Hurr K, Huff V, Clayman GL, Luna MA, Batsakis JG. Microsatellite instability in preinvasive and invasive head and neck squamous carcinoma. Am J Pathol 148(6):2067-72, 1996. e-Pub 1996. PMID: 8669490.
El-Naggar AK, Hurr K, Huff V, Luna MA, Goepfert H, Batsakis JG. Allelic loss and replication errors at microsatellite loci on chromosome 11p in head and neck squamous carcinoma: association with aggressive biological features. Clin Cancer Res 2(5):903-7, 1996. e-Pub 1996. PMID: 9816248.
Priest JR, Watterson J, Strong L, Huff V, Woods WG, Byrd RL, Friend SH, Newsham I, Amylon MD, Pappo A, Mahoney DH, Langston C, Heyn R, Kohut G, Freyer DR, Bostrom B, Richardson MS, Barredo J, Dehner LP. Pleuropulmonary blastoma: a marker for familial disease. J Pediatr 128(2):220-4, 1996. e-Pub 1996. PMID: 8636815.
Mars WM, Patmasiriwat P, Maity T, Huff V, Weil MM, Saunders GF. Inheritance of unequal numbers of the genes encoding the human neutrophil defensins HP-1 and HP-3. J Biol Chem 270(51):30371-6, 1995. e-Pub 1995. PMID: 8530462.
El-Naggar AK, Hurr K, Batsakis JG, Luna MA, Goepfert H, Huff V. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 55(12):2656-9, 1995. e-Pub 1995. PMID: 7780981.
Szabo J, Heath B, Hill VM, Jackson CE, Zarbo RJ, Mallette LE, Chew SL, Besser GM, Thakker RV, Huff V, Leppert MF, Heath H. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 56(4):944-50, 1995. e-Pub 1995. PMID: 7717405.
Huff V, Jaffe N, Saunders GF, Strong LC, Villalba F, Ruteshouser EC. WT1 exon 1 deletion/insertion mutations in Wilms tumor patients, associated with di- and trinucleotide repeats and deletion hotspot consensus sequences. Am J Hum Genet 56(1):84-90, 1995. e-Pub 1995. PMID: 7825606.
Huff V. Parental origin of WT1 mutations and mental retardation in WAGR syndrome. Nat Genet 8(1):13-4, 1994. e-Pub 1994. PMID: 7987386.
Martinerie C, Huff V, Joubert I, Badzioch M, Saunders G, Strong L, Perbal B. Structural analysis of the human nov proto-oncogene and expression in Wilms tumor. Oncogene 9(9):2729-32, 1994. e-Pub 1994. PMID: 7520150.
Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 54(9):2331-3, 1994. e-Pub 1994. PMID: 8162576.
Choi K. Small supersymmetric phases in string-inspired supergravity. Phys Rev Lett 72(11):1592-1595, 1994. e-Pub 1994. PMID: 10055651.
Fraizer GC, Wu YJ, Hewitt SM, Maity T, Ton CC, Huff V, Saunders GF. Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter. J Biol Chem 269(12):8892-900, 1994. e-Pub 1994. PMID: 8132626.
Coppes MJ, Huff V, Pelletier J. Denys-Drash syndrome: relating a clinical disorder to genetic alterations in the tumor suppressor gene WT1. J Pediatr 123(5):673-8, 1993. e-Pub 1993. PMID: 8229473.
Chao LY, Huff V, Tomlinson G, Riccardi VM, Strong LC, Saunders GF. Genetic mosaicism in normal tissues of Wilms' tumour patients. Nat Genet 3(2):127-31, 1993. e-Pub 1993. PMID: 8388768.
Miwa H, Tomlinson GE, Timmons CF, Huff V, Cohn SL, Strong LC, Saunders GF. RNA expression of the WT1 gene in Wilms' tumors in relation to histology. J Natl Cancer Inst 84(3):181-7, 1992. e-Pub 1992. PMID: 1311774.
Huff V, Reeve TE, Leppert M, Strong LC, Douglass EC, Geiser CF, Li FP, Meadows A, Callen D, Lenoir G, Saunders GF. Nonlinkage of 16q markers to familial predisposition to Wilms' tumor. Cancer Res 52(21):6117-20, 1992. e-Pub 1992. PMID: 1356625.
Ton CC, Huff V, Call KM, Cohn S, Strong LC, Housman DE, Saunders GF. Smallest region of overlap in Wilms tumor deletions uniquely implicates an 11p13 zinc finger gene as the disease locus. Genomics 10(1):293-7, 1991. e-Pub 1991. PMID: 1646159.
Huff V, Miwa H, Haber DA, Call KM, Housman D, Strong LC, Saunders GF. Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. Am J Hum Genet 48(5):997-1003, 1991. e-Pub 1991. PMID: 1673293.
Levinson AK, Johnson DE, Strong LC, Pathak S, Huff V, Saunders GF. Familial renal cell carcinoma: hereditary or coincidental?. J Urol 144(4):849-51, 1990. e-Pub 1990. PMID: 2398557.
Huff V, Meadows A, Riccardi VM, Strong LC, Saunders GF. Parental origin of de novo constitutional deletions of chromosomal band 11p13. Am J Hum Genet 47(1):155-60, 1990. e-Pub 1990. PMID: 1971994.
Ton CC, Huff V, Weil MM, Strong LC, Saunders GF. A BglII RFLP detected by the probe JA8-1 at human chromosome band 11p13 (D11S417). Nucleic Acids Res 18(4):1084, 1990. e-Pub 1990. PMID: 1969141.
Huff V, Compton DA, Strong LC, Saunders GF. A panel of restriction fragment length polymorphisms for chromosomal band 11p13. Hum Genet 84(3):253-7, 1990. e-Pub 1990. PMID: 1968033.
Weil MM, Huff V, Compton DA, Strong LC, Saunders GF. An XmnI polymorphism detected by a human genomic clone from chromosomal band 11p13 [D11S416]. Nucleic Acids Res 18(3):689, 1990. e-Pub 1990. PMID: 1968626.
Huff V, Cai W, Glorioso JC, Levine M. The carboxy-terminal 41 amino acids of herpes simplex virus type 1 glycoprotein B are not essential for production of infectious virus particles. J Virol 62(11):4403-6, 1988. e-Pub 1988. PMID: 2845151.
Huff V, Compton DA, Chao LY, Strong LC, Geiser CF, Saunders GF. Lack of linkage of familial Wilms' tumour to chromosomal band 11p13. Nature 336(6197):377-8, 1988. e-Pub 1988. PMID: 2848200.
Huff V, Compton D, Lewis W, Jones C, Strong LC, Saunders GF. An EcoRI polymorphism associated with a human genomic clone from band 11p13. Nucleic Acids Res 15(18):7651, 1987. e-Pub 1987. PMID: 2889190.
DuFrain RJ, Littlefield LG, Morrison WD, Huff VD, Hutton D. Evaluation of chemically induced cytogenetic lesions in rabbit oocytes. III. A postimplantation analysis of streptonigrin effects. Mutat Res 127(1):73-79, 1984. e-Pub 1984. PMID: 6727905.
Morrison WD, Huff V, Littlefield LG, DuFrain RJ. Chromosome preparations from rabbit preovulatory oocytes. Mutat Res 119(2):169-75, 1983. e-Pub 1983. PMID: 6828053.
Huff V, DuFrain RJ, Littlefield LG. SCE frequencies in rabbit lymphocytes as a function of time after an acute dose of cyclophosphamide. Mutat Res 94(2):349-57, 1982. e-Pub 1982. PMID: 7110178.
Morrison WD, Huff V, Colyer SP, DuFrain RJ, Littlefield LG. Cytogenetic effects of cis-platinum(II)diamminedichloride in vivo. Environ Mutagen 3(3):265-74, 1981. e-Pub 1981. PMID: 7196834.
Huff V, Littlefield LG, DuFrain RJ, Wilmer JL. Factors affecting the sensitivity of rabbit lymphoid and bone marrow cells to Streptonigrin-induced chromosome aberrations. Cytogenet Cell Genet 30(1):15-24, 1981. e-Pub 1981. PMID: 7261679.
Palculict TB, Ruteshouser EC, Strong LC, Dome J, Meadows A, Huff V. The Role of 2p24 Germline Microduplication of MYCN and Flanking Genes in Familial Wilms Tumor (FWT) and Associated Subsequent Development of Brain Tumors. Genes, Chromosomes & Cancer.

Invited Articles

Ruteshouser EC, Huff V. Blotting Assays. Cancer Bulletin 47:268-271, 1995. e-Pub 1995.
Huff V. Inheritance and functionality of Wilms tumor genes. Cancer Bulletin 46:254-259, 1994. e-Pub 1994.
Huff V, Compton DA, Weil M, Strong LC, Saunders GF. Molecular cytogenetics of Wilms' tumor. Cancer Bulletin 41:312-318, 1989. e-Pub 1989.
Huff V. Genetic linkage analysis of familial Wilms' tumor. OncoLog 34:4-8, 1989. e-Pub 1989.

Review Articles

Perotti D, Williams RD, Wegert J, Brzezinski J, Maschietto M, Ciceri S, Gisselsson D, Gadd S, Walz AL, Furtwaengler R, Drost J, Al-Saadi R, Evageliou N, Gooskens SL, Hong AL, Murphy AJ, Ortiz MV, O'Sullivan MJ, Mullen EA, van den Heuvel-Eibrink MM, Fernandez CV, Graf N, Grundy PE, Geller JI, Dome JS, Perlman EJ, Gessler M, Huff V, Pritchard-Jones K. Hallmark discoveries in the biology of Wilms tumour. Nat Rev Urol 21(3):158-180, 2024. e-Pub 2024. PMID: 37848532.
Huff V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 11(2):111-21, 2011. e-Pub 2011. PMID: 21248786.
Ruteshouser EC, Huff V. Familial Wilms tumor. Am J Med Genet C Semin Med Genet 129(1):29-34, 2004. e-Pub 2004. PMID: 15264270.
Huff V. Wilms tumor genetics. Am J Med Genet 79(4):260-7, 1998. e-Pub 1998. PMID: 9781905.
Huff V, Saunders GF. Wilms tumor genes. Biochim Biophys Acta 1155(3):295-306, 1993. e-Pub 1993. PMID: 8268188.

Professional Educational Materials

Dome JS, Huff V. Wilms Tumor Overview. In: GeneReviews at GeneTests: Medical Genetics Information Resource. GeneReviews [Internet], 2013.
Dome JS, Huff V. Wilms Tumor Predispositon. In: GeneReviews at GeneTests: Medical Genetics Information Resource. GeneReviews[Internet], 2013.
Dome JS, Huff V. Wilms Tumor Overview. In: GeneReviews at GeneTests: Medical Genetics Information Resource, 2009.
Dome JS, Huff V. Wilms Tumor Overview. In: GeneReviews at GeneTests: Medical Genetics Information Resource [online database supported by the NIH], 2005.
Dome JS, Huff V. Wilms Tumor Overview. In: GeneReviews at GeneTests: Medical Genetics Information Resource [online database supported by the NIH], 2003.
Huff V. Clinical application of molecular biology techniques. In: Medical Oncology: A Comprehensive Review. (Review course sponsored by M.D. Anderson Cancer Center for medical oncology boards. Course syllabus composed of comprehensive lecture outlines and video tape of lectures), 2000.
Dome JS, Huff V. Wilms Tumor Overview, 1993.

Abstracts

Palculict B, Ruteshouser C, Fan Y, Wang W, Huff V. Identification of Familial Wilms Tumor Predisposition Genes Using Whole Genome Sequencing. ASHG Annual Meeting, San Diego, CA, 2014. e-Pub 2014.
Mokkapati S, Niopek K, Huang L, Cunniff KJ, Ruteshouser EC, deCaestecker M, Finegold MJ, Huff V. β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. S. Baylor College of Medicine Liver Cancer Symposium, 2014. e-Pub 2014.
Mokkapati S, Niopek K, Huang L, Cunniff KJ, Ruteshouser EC, deCaestecker M, Finegold MJ, Huff V. β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. FASEB Liver Biology: Fundamental Mechanisms and Translational Applications meeting, Colorado, 2014. e-Pub 2014.
Le H, Mokkapati S, Hu Q, Huff V. Impact of Kidney Progenitor Cell Differentiation Status in Wilms Tumorigenesis. AACR Annual Meeting in Washington DC, 2013. e-Pub 2013.
Le H, Mokkapati S, Hu Q, Huff V. Impact of Kidney Progenitor Cell Differentiation Status in Wilms Tumorigenesis. CPRIT Annual Symposium, Austin, 2012. e-Pub 2012.
Le H, Mokkapati S, Hu Q, Huff V. Impact of Kidney Progenitor Cell Differentiation Status in Wilms Tumorigenesis. CPRIT Annual Symposium, Austin, 2011. e-Pub 2011.
Subbiah V, Huff V, Wolff J, Ketonen L, Lang F, Stewart J, Langford L, Herzog CE. Bilateral Gonadoblastoma with Dysgerminoma and Pilocytic Astrocytoma with WT1 GT-IVS 9 Mutation - a 46 XY Phenotypic Female with Frasier Syndrome and Review of Literature. ASPHO, San Diego, CA, 2009. e-Pub 2009.
Hu, Q. Inactivation of WT1 and Overexpression of IGF2 Results in Wilms Tumorigenesis in Mice. Mechanisms and Models of Cancer, Cold Spring Harbor, NY, 2008. e-Pub 2008.
Ruteshouser EC, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about 30% of tumors. Sixth International Conference on the Biology of Childhood Renal Tumors. Chamonix, France, 2008. e-Pub 2008.
Ruteshouser EC, Alam N, Robinson SM, Huff V. Overlap between WTX and WT1 mutations in Wilms tumors. American Society of Human Genetics Annual Meeting, 2007. e-Pub 2007.
Gao F, Maiti S, Alam N, Zhang Z, Deng JM, Behringer RR, Lecureeuil C, Guillou F, Huff V. Wt1 is required for Sox9 expression and maintenance of tubular architecture in the developing testes. Texas Forum on Reproductive Sciences, 12th Annual Meeting, 2006. e-Pub 2006.
Gao F, Maiti S, Alam N, Zhang Z, Deng JM, Behringer RR, Lecureuil C, Guillou F, Huff V. The Wilms tumor gene, Wt1, is required for Sox9 expression and normal tubular architecture in the developing testes. Fourth International Symposium on the Biology of Vertebrate Sex Determination, 2006. e-Pub 2006.
Gao F, Huff V. Mouse Wt1 Missense Mutation Results in Female Subfertility. Annual Texas Forum on Female Reproduction, Houston, 2005. e-Pub 2005.
Gao F, Maiti S, Sun G, Huff V. Mouse Wt1 missense mutation results in glomerulosclerosis characteristic of human Denys-Drash syndrome. 5th International Podocyte Conference, Seattle, 2004. e-Pub 2004.
Ruteshouser EC, Hendrickson BW, Colella S, Krahe R, Pinto L, Huff V. Genome-wide LOH Analysis of WT1-Wildtype and WT1-Mutant Wilms Tumor. Am Soc Hum Genet annual meeting, Toronto, 2004. e-Pub 2004.
Krahe R, Hendrickson BW, Colella S, Alam R, Wright F, Huff V. Genome anatomy of Wilms tumor: genome-wide LOH analysis reveals unique signatures and tumor subgroups. American Society of Human Genetics, annual meeting, Los Angeles, 2003. e-Pub 2003.
Hendrickson BW, Colella S, Alam R, Huff V, Krahe R. Genome-wide LOH Analysis of Wilms Tumor (WT) Reveals Complex and Unique Signatures that Identify Tumor Subgroups. Oncogenomics meeting, Dublin, 2002. e-Pub 2002.
Huff V, Alam R, Cabello S, Hendrickson B, Krahe R. Genome-wide loss of heterozygosity analysis for genetically distinct subsets of Wilms tumors. Biology of Childhood Cancer Meeting, London, 2002. e-Pub 2002.
McDonald M, Huff V. Clinical effects of WT1 mutations in a study of 118 Wilms tumor patients. Am J Hum Genet 65:A138, 1999. e-Pub 1999.
McDonald M, Huff V. Clinical effects of WT1 mutations in a study of 118 Wilms tumor patients. Am J Hum Genet 65:A138, 1999. e-Pub 1999.
Pannu H, Huff V. Identification and characterization of genes differentially expressed in a subset of Wilms tumors with non-functional WT1. Am J Hum Genet 65:A314, 1999. e-Pub 1999.
Clericuzio CL, Byrn F, Huff V. A novel WT1 mutation in Frasier syndrome: support for the concept of the "WT1 spectrum disorder. Am J Hum Genet 65:A145, 1999. e-Pub 1999.
Hussong J, Perkins S, Pysher T, Beckwith B, Huff V, Coffin C. Familial Wilms' tumor with neural elements: histologic and immunophenotypic analysis. Soc Pediatr Path, 1997. e-Pub 1997.
Gunning KB, Huff V. Analysis of possible abnormal RNA processing in primary Wilms tumors. Am J Hum Genet 57:A66, 1995. e-Pub 1995.
Huff V, Schneider NR, Strong LC, Timmons CF, Tomlinson GF. Somatic mutation of the Wilms tumor (WT) suppressor gene, WT1, in a WT patient with a constitutional 2;15 unbalanced translocation: evidence for the involvement of multiple genes in the etiology of a Wilms tumor. Am J Hum Genet 57:A66, 1995. e-Pub 1995.
Pannu H, Huff V. In vivo expression of WT1, IGF2, and H19 in Wilms tumor. Proc Amer Assoc Cancer Res 36:193, 1995. e-Pub 1995.
Huff V, Saunders GF, Strong LC, Villalba F. WT1 exon 1 deletion/insertion mutations in Wilms tumor patients associated with di- and trinucleotide repeats and deletion hotspot consensus sequences. Am J Hum Genet 55:A33, 1994. e-Pub 1994.
Coppes MJ, Pelletier J, Huff V. Constitutional WT1 mutations: an additional diagnostic criterion for the Denys-Drash syndrome. Int Soc Pediatr Oncol, 1993. e-Pub 1993.
Saunders GF, Huff V, Strong LC. Molecular genetics of Wilms tumor. Anticancer Research 12:1782, 1992. e-Pub 1992.
Huff V, Chao L, Tomlinson G, Strong LC, Saunders GF. Somatic mosaicism for chromosome 11p loss of heterozygosity in normal tissue DNA from Wilms tumor patients. Amer J Hum Genet 51:A38, 1992. e-Pub 1992.
Huff V, Villalba F, Strong LC, Saunders GF. Alteration of the WT1 gene in patients with Wilms' tumor and genitourinary anomalies. Amer J Hum Genet Suppl 49:44, 1991. e-Pub 1991.
Huff V, Miwa H, Haber D, Housman D, Strong LC, Saunders GF. Intragenic germinal deletion in bilateral Wilms' tumor: evidence that WT33 identifies a WT gene (WT1) and support for the two-mutation model. Amer J Hum Genet 47:A9, 1990. e-Pub 1990.
Huff V, Compton DA, L-Y C, Riccardi VM, Strong LC, Saunders GF. Parental origin of de novo constitutional deletions of chromosomal band 11p13. Amer J Hum Genet 45:A89, 1989. e-Pub 1989.
Huff V, Compton DA, L-Y C, Strong LC, Saunders GF. Lack of linkage of familial Wilms' tumor to chromosomal band 11p13. Amer J Human Genet 43:A99, 1988. e-Pub 1988.
Huff V, Compton DA, L-Y C, Schroeder WT, Strong LC, Saunders GF. Chromosome 11p13 alterations in Wilms' tumor. Amer Soc Pediatr Hematol Oncol, 1988. e-Pub 1988.
Huff V, L-Y C, Schroeder WT, Riccardi VM, Strong LC, Saunders GF. Genetic alterations in bilateral Wilms' tumor. Amer J Hum Genet 41:A28, 1987. e-Pub 1987.
Gelehrter TD, Heaton JH, Huff V. Regulation of insulin and growth factor responsiveness in hepatoma cells. Clin. Res 30:524A, 1982. e-Pub 1982.
Huff V, Hutton D, DuFrain R, Littlefield LF, Wilmer J. Streptonigrin and cyclophosphamide induced chromosome lesions in somatic cells vs. oocytes of the rabbit. Environ Mutagen 2:254, 1980. e-Pub 1980.
Morrison WD, Huff V, Colyer S, Littlefield F, DuFrain RJ. Cytogenetic effects of cis-platinum(II)diaminedichloride (cis-PDD) on rabbit and human cells. Environ Mutagenesis 2:298, 1980. e-Pub 1980.
Huff V, Hutton DG, DuFrain RJ, Littlefield LF. Comparison of chromosome lesion frequencies in rabbit bone marrow following a single of double injection of cyclophosphamide. Proc Soc Exptl Biol Med 4:19, 1979. e-Pub 1979.
Huff V, Chen JP, Chua WA. Radioimmunoassay of fibrinogen-fibrin degradation products in plasma and serum: assay for fragments Y neoantigens. Proc Fed Amer Soc Exptl Biol 37:957, 1978. e-Pub 1978.

Book Chapters

Dome J, Ehlich P, Fernandez C, Geller J, Hill DA, Huff V, Kalapurakal J. Renal Tumors. In: Principles and Practice of Pediatric Oncology. Pizzo and Poplack, 2013.
Anderson PM, Dhamne CA, Huff V. Neoplasms of the Kidney. In: Nelson Textbook of Pediatrics. Saunders Press, 2011.
Jaffe N, Huff V. Neoplasms of the Kidney. In: Nelson Textbook of Pediatrics. 18. Saunders Press, 2140-2143, 2007.
Jaffe N, Huff V. Neoplasms of the Kidney. In: Nelson Textbook of Pediatrics. 17. Saunders Press, 1711-1714, 2003.
Huff V. WT1 in tumorigenesis and development. In: Proceedings of the Third Symposium "Maleformation Syndromes and Neoplastic Growth". Catholic University, 2000.
Huff V, Compton DA, Weil MM, Strong LC, Saunders GF. Molecular genetics of Wilms' tumor. In: Cell Function and Disease. Plenum Press, 7-24, 1988.
Daw Bitar N, Huff V, Anderson P. Neoplasms of the Kidney. In: Nelson Textbook of Pediatrics. Saunders Press.

Less

CV information above last modified July 22, 2026

Vicki Huff

About Dr. Vicki Huff

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Abstracts

Book Chapters

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Vicki Huff

About Dr. Vicki Huff

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Abstracts

Book Chapters

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson